epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2021-20-2-83-92epidemiology-1229Research ArticleОБЗОРREVIEWВакцинация как вариант решения вопроса резистентности S. pneumoniaeVaccination as a solution of the issue of resistance S. pneumoniaehttps://orcid.org/0000-0002-6231-246XРубанА. П.RubanH. P.

Анна Петровна Рубан, к. м. н., доцент, доцент кафедры поликлинической педиатрии

Минск

Hanna Р. Ruban, Cand. Sci. (Med.), associate professor, Department of ambulatory pediatrics

Minsk

https://orcid.org/0000-0002-9178-9734СтручС. В.StruchS. V.

Светлана Васильевна Струч, к. м. н., старший медицинский менеджер

Москва

Svetlana V. Struch, Cand. Sci. (Med.), Senior Medical Manager

Moscow

Svetlana.Struch@pfizer.comГУО «Белорусская медицинская академия последипломного образования»БеларусьState Educational Establishment «Belarusian Medical Academy of Postgraduate EducatBelarusООО «Пфайзер Инновации»РоссияPfizer Innovation LLCRussian Federation2021030520212028392Copyright © Рубан А.П., Струч С.В., 20212021Рубан А.П., Струч С.В.Ruban H.P., Struch S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/1229

Актуальность. В настоящее время проблема роста антимикробной резистентности (АМР) является крайне актуальной для мирового здравоохранения. Значимость проблемы обусловлена широким использованием антибактериальных средств, ещё более она актуализирована на фоне пандемии новой коронавирусной инфекции. Полипрагмазия антибиотиков влечёт за собой изменение свойств микробных агентов в сторону снижения их чувствительности и, таким образом, может привести к потере целого ряда возможных рычагов влияния на различных возбудителей инвазивных бактериальных заболеваний. Одной из мер по снижению АМР является вакцинопрофилактика пневмококковой инфекции. Повышение осведомленности врачей в данном вопросе также будет способствовать решению задач по снижению АМР. Цель работы. Осветить стоящие перед медицинским сообществом основные связанные с АМР задачи и возможные способы их решения. Проанализировать литературные данные о вкладе вакцинопрофилактики пневмококковой инфекции в снижение числа пневмококковых заболеваний и потребности применения антибактериальной терапии. Оценить бремя инвазивных пневмококковых заболеваний в мире и в Республике Беларусь (РБ). Выявить проблемные моменты в осведомлённости врачей по вопросам иммунопрофилактики пневмококковой инфекции, её эффективности и влиянию на АМР. Выводы. Специфическая вакцинопрофилактика пневмококковой инфекции через снижение уровня заболеваемости и потребности в антибактериальной терапии вносит существенный вклад в решение вопроса сдерживания АМР.

Relevance Antimicrobial resistance (AMR) is a growing acute global health issue. Uncontrolled combined use of antibiotics determines changes in the microbial agents' properties, leading to a decrease of susceptibility to antimicrobial substances and increasing the probability of severe invasive bacterial infections with limited possibilities to treat them. Vaccination against pneumococcal infection as well as improvement of the health care providers awareness can be considered as part of AMR management strategies. A number of epidemiological observations have been published indicating a change in antimicrobial resistance to Streptococcus pneumoniae following the implementation of the national infant immunization program against pneumococcal infection. Aim. To analyze the literature data on the pneumococcal vaccination contribution to the reduction of the number of pneumococcal diseases and the need for antibacterial therapy and to assess the burden of invasive pneumococcal diseases globally and in the Republic of Belarus (RB) and to identify gaps in the awareness of practicing physicians on pneumococcal infection immunoprophylaxis, its' effectiveness and impact on AMR. Conclusions. WHO considers and promote vaccination as an AMR containment measure. There are a lot of publications with the examples of countries with pneumococcal infection pediatric national immunization programs (NIP) and epidemiological data on changes in the S.pneumoniae sensitivity to antibacterial drugs after the start of the NIP. During the period of the mass PCV immunization and the subsequent drift of strains the sensitivity to antimicrobials may return. In Israel 88% and 93% reduction of otitis media cases caused by resistant to penicillin and macrolides vaccine types of S.pneumoniae after the phased introduction of PCV7 and PCV13 to the infant NIP, comparing to the period before vaccination introduction. A decrease in the frequency of bacteremia in combination with a sharp decrease in the proportion of penicillin-resistant pneumococcal isolates (from 50.9% to 5.3%) is also described. In France the proportion of S.pneumoniae strains with reduced susceptibility or resistance to penicillin declined from 47.1% to 39% after the start of PCV13 NIP; researchers also noted a decrease in antibiotic-resistant isolates of S.pneumoniae in children with otitis media: by 26, 31, 55, 29 and 57%, respectively, to penicillin, amoxicillin, cefotaxime, erythromycin and co-trimoxazole to in 2011. A study in Germany revealed a decrease in macrolide-resistant IPD strains after the start of PCV13 use of (in children 8.2%; in adults 8.8%) compared with the period after the introduction of PCV7 (17.3% and 13.0%) and especially in the cohort of children compared with the period before the use of PCV7 (24.8% and 13.3%). In Scotland, there was a decrease in the number of penicillin-resistant strains isolated from the blood of patients with IPD after the introduction of PCV13 into the NIP. The publication of the results of three parallel studies in Finland evaluated the effectiveness of PCV10 in reducing the number of IPD caused by vaccine-specific serotypes of PCV10 by 93%, 98% and 100%, respectively. At the same time, the effectiveness against «related» PCV10 serotypes was equal to 46%, 51% and 78%, respectively, and the estimated effectiveness against unrelated PCV10 serotypes was negative. Composition and resistance profile of the lower respiratory tract microflora isolated from sputum pneumococcal strains in children in 2016–2018, demonstrated up to 72.4% resistance to macrolides, 31.3% resistance to cefotaxime and 8.3% – to ceftriaxone. Spn serotypes structure in under 5 years of age children with meningitis was characterized by relatively high uniformity. Majority (92%) of multiresistant meningeal strains are covered by current PCVs. An anonymous questionnaire showed pediatricians' insufficient awareness about current approaches to pneumococcal infection prevention, underestimation of IPD risks and complications, and the impact of vaccination on reducing AMR. Additional education is required to increase the level of knowledge and understanding of the PCVs role in AMR reduction. PCV NIP introduction will provide additional opportunities to reduce AMR in the Republic of Belarus.

вакцинацияантимикробная резистентностьпневмококквакцинапневмококковая инфекцияvaccinationantimicrobial resistancepneumococcusvaccinepneumococcal infectionПубликация подготовлена при финансовой поддержке компании Пфайзер, МоскваThe publication was prepared with financial support by Pfizer, MoscowReferencesO’Neill J. Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. 2014. Доступно на: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdfO’Neill J. Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. 2014. Available at: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf.ВОЗ. Глобальный план действий по борьбе с устойчивостью к противомикробным препаратам. Доступно на: https://apps.who.int/iris/bitstream/handle/10665/254884/9789244509760-rus.pdf?sequence=1.WHO. Global Action Plan on Antimicrobial Resistance. 2016. Available at: https://apps.who.int/iris/bitstream/handle/10665/254884/9789244509760-rus.pdf?sequence=1.WHO. GLASS country enrollment status, as of 16 October 2019. Доступно на: https://www.who.int/glass/country-participation/map-participation-AMR-20191016.jpgWHO. GLASS country enrollment status, as of 16 October 2019. Available at: https://www.who.int/glass/country-participation/map-participation-AMR-20191016.jpgThe role of vaccination in reducing antimicrobial resistance (AMR). Доступно на: http://www.vaccineseurope.eu/wp-content/uploads/2016/11/VE-policy-paper-on-therole-of-vaccines-in-reducing-AMR-2016-FIN.pdf . Accessed: 26 Dec 2020.Vaccines Europe paper. The role of vaccination in reducing antimicrobial resistance (AMR) Available at: http://www.vaccineseurope.eu/wp-content/uploads/2016/11/VE-policy-paper-on-the-role-of-vaccines-in-reducing-AMR-2016-FIN.pdf. Accessed: 26 Dec 2020.Таточенко В. К., Озерецковский Н. А. Иммунопрофилактика-2018: справочник, 13-е изд., расширенное. М: Боргес; 2018. 272 с.Tatochenko V.K., Ozereckovskij N.A. Immunoprofilaktika-2018-spravochnik-13-e-izd-rasshirennoe-M-borges-2018-272-s (In Russ.).Kennedy DA, Read AF. 2017 Why does drug resistance readily evolve but vaccine resistance does not? Proc. R. Soc. B284: 20162562. http://dx.doi.org/10.1098/rspb.2016.2562Kennedy DA, Read AF. 2017 Why does drug resistance readily evolve but vaccine resistance does not? Proc. R. Soc. B284: 20162562. http://dx.doi.org/10.1098/rspb.2016.2562O’Neill J. The review on antimicrobial resistance [Internet]. Vaccines and alternative approaches: reducing our dependence on antimicrobials. February 2016. Доступно на: https://amr-review.org/sites/default/files/Vaccines%20and%20alternatives_v4_LR.pdf Accessed: 26 Dec 2020.O’Neill J. The review on antimicrobial resistance. Vaccines and alternative approaches: reducing our dependence on antimicrobials. February 2016. Available at: https://amr-review.org/sites/default/files/Vaccines%20and%20alternatives_v4_LR.pdf. - Accessed: 26 Dec 2020.Claire Janoir, Agnès Lepoutre, et al. Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After 13-valent Pneumococcal Conjugate Vaccine Implementation in France. Open Forum Infect Dis. 2016 Feb 2;3(1) https://doi.org/10.1093/ofid/ofw020Claire Janoir, Agnès Lepoutre, et al. Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After13-valent Pneumococcal Conjugate Vaccine Implementation in France. Open Forum Infect Dis. 2016 Feb 2;3(1) https://doi.org/10.1093/ofid/ofw020ECDC. Invasive pneumococcal disease. Annual Epidemiological Report for 2018 Доступно на: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_IPD.pdf. Accessed: 26 Dec 2020.ECDC. Invasive pneumococcal disease. Annual Epidemiological Report for 2018 Available at: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_IPD.pdf. - Accessed: 26 Dec 2020.ECDC [Internet]. Surveillance of antimicrobial resistance in Europe 2017. Annual report of the EARS-Net. Available at: http://www.belriem.by/images/docs/problemtitov/EARS-NET2017.pdf. Accessed: 26 Dec 2020.ECDC. Surveillance of antimicrobial resistance in Europe 2017. Annual report of the EARS-Net. Available at: http://www.belriem.by/images/docs/problemtitov/EARS-NET2017.pdf. Accessed: 26 Dec 2020.Намазова-Баранова Л.С., Федосеенко М.В., Вишнёва Е.А. и др. Теоретические основы и реальные результаты: обзор материалов по вакцинопрофилактике пневмококковой инфекции в мире. Педиатрическая фармакология. 2018; 15 (1): 58–74. doi: 10.15690/pf.v15i1.1844).Leyla S. Namazova-Baranova, Marina V. Fedoseenko, Elena A. Vishneva, Lilia R. Selimzianova, Daria S. Chemakina. Theoretical Background and Real Results: A Data Review on Vaccine Prevention of Pneumococcal Infection in the World. Pediatricheskaya farmakologiya– Pediatric pharmacology. 2018; 15(1): 58–74 (In Russ.). doi: 10.15690/pf.v15i1.1844).Чучалин А.Г., Брико Н.И., Авдеев С.Н. и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019; 29(1): 19–34. DOI: 10.18093/0869-0189-2019-29-1-19-34Chuchalin A.G., Briko N.I., Avdeev S.N., et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Russian Pulmonology. 2019; 29 (1): 19–34 (In Russ.). DOI: 10.18093/0869-0189-2019-29-1-19-34Таточенко В.К., Озерецковский Н.А. Иммунопрофилактика-2020: справочник. М: ПедиатрЪ, 2020.Tatochenko V.K., Ozeretskovsky N.A. Immunoprophylaxis 2020: a guide. Moscow: Pediatr, 2020 (In Russ.).Fein A.M. Pneumonia in the elderly: overview of diagnostic and therapeutic approaches. Clin Infect Dis.1999; 28(4):726–729 https://doi.org/10.1086/515218.Fein A.M. Pneumonia in the elderly: overview of diagnostic and therapeutic approaches. Clin Infect Dis.1999; 28(4):726–729. https://doi.org/10.1086/515218Бобылев А. А., Рачина С. А., Авдеев С. Н. и др. Этиология внебольничной пневмонии улиц с хронической сердечной недостаточностью. Пульмонология. 2019;29(3):293–301. DOI: 10. 18093/0869-0189-2019-29-3-293-301.Bobylev A.A., Rachina S.A., Avdeev S.N., et al. Etiology of community-acquired pneumonia in patients with chronic heart failure. Russian Pulmonology. 2019; 29 (3): 293– 301 (in Russ.). DOI: 10.18093/0869-0189-2019-29-3-293-30.CDC. Active Bacterial Core surveillance (ABCs). Доступно на: https://www.cdc.gov/abcs/reports-findings/survreports/spneu-types.html. Accessed: 26 Dec 2020.CDC. Active Bacterial Core surveillance (ABCs). Available at: https://www.cdc.gov/abcs/reports-findings/survreports/spneu-types.html. - Accessed: 26 Dec 2020.Tomczyk S., Lynfield R., Schaffner W., et al. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clin Infect Dis. 2016;62(9):1119–1125. doi: 10.1093/cid/ciw067.Tomczyk S., Lynfield R., Schaffner W., et al. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clin Infect Dis. 2016;62(9):1119-1125. doi: 10.1093/cid/ciw067.Dagan R., Klugman K. Impact of Conjugate Pneumococcal Vaccines on Antibiotic Resistance, Lancet Infect Dis. 2008Dec;8(12):785–95. doi: 10.1016/S1473-3099(08)70281-0.Dagan R., Klugman K. Impact of Conjugate Pneumococcal Vaccines on Antibiotic Resistance, Lancet Infect Dis. 2008 Dec;8(12):785–95. doi: 10.1016/S1473-3099(08)70281-0.Berezin E.N., Jarovsky D., Cardoso M.R., et al. Invasive pneumococcal disease among hospitalized children in Brazil before and after the introduction of a pneumococcal conjugate vaccine. Vaccine. 38 (2020) 1740–1745. https://doi.org/10.1016/j.vaccine.2019.12.038.Berezin E.N., Jarovsky D., Cardoso M.R., et al. Invasive pneumococcal disease among hospitalized children in Brazil before and after the introduction of a pneumococcal conjugate vaccine. Vaccine. 38 (2020) 1740–1745. https://doi.org/10.1016/j.vaccine.2019.12.038Moreno G.C., Imbachi L.F., Leal A.L., et al. (2020) Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10, Human Vaccines & Immunotherapeutics, 16:9, 2300–2306, DOI: 10.1080/21645515.2019.1710411.Moreno G.C., Imbachi L.F., Leal A.L., et al. (2020) Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10, Human Vaccines & Immunotherapeutics, 16:9, 2300-2306, DOI: 10.1080/21645515.2019.1710411.Shalom Ben-Shimol, Noga Givon-Lavi, Eugene Leibovitz, et al. Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media, Clinical Infectious Diseases, Volume 63, Issue 5, 1 September 2016, Pages 611–618, https://doi.org/10.1093/cid/ciw347.Shalom Ben-Shimol, Noga Givon-Lavi, Eugene Leibovitz, et al. Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media, Clinical Infectious Diseases, Volume 63, Issue 5, 1 September 2016, Pages 611–618, https://doi.org/10.1093/cid/ciw347.Ben-Shimol S, et al. Presented at: 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 12–16, 2015; Leipzig, Germany. Abstract 0225.Ben-Shimol S, et al. Presented at: 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 12-16, 2015; Leipzig, Germany. Abstract 0225.Dagan R., Avital D., Givon-Lavi N., et al. Rates dynamics of chest radiography examination (CRE) as a marker of pneumococcal conjugate vaccine (PCV) impact on pediatric lower respiratory tract infections. Presented at: 36rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 28 – June, 2015; Malmo; Sweden. May Abstract 0266.Dagan R., Avital D., Givon-Lavi N., et al. Rates dynamics of chest radiography examination (CRE) as a marker of pneumococcal conjugate vaccine (PCV) impact on pediatric lower respiratory tract infections. Presented at: 36rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 28 – June, 2015; Malmo; Sweden. May Abstract 0266.Geller D., Almog R., Geffen Y., et al. The pneumococcal vaccine effect on the epidemiology of community acquired bacteremia (CAB) among children in Israel during the years 2004-2016. Presented at: 36rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 28 – June, 2015; Malmo; Sweden. May Abstract 0449.Geller D., Almog R., Geffen Y., et al. The pneumococcal vaccine effect on the epidemiology of community acquired bacteremia (CAB) among children in Israel during the years 2004-2016. Presented at: 36rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 28 – June, 2015; Malmo; Sweden. May Abstract 0449.Angoulvant F, Cohen R., Doitet C., et al. Trends in antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from nasopharyngeal flora in children with acute otitis media in France before and after 13 valent pneumococcal conjugate vaccine introduction. BMC Infect Dis. 2015;15:236. DOI 10.1186/s12879-015-0978-9.Angoulvant F, Cohen R., Doitet C. Trends in antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from nasopharyngeal flora in children with acute otitis media in France before and after 13 valent pneumococcal conjugate vaccine introduction. BMC Infect Dis. 2015;15:236. DOI 10.1186/s12879-015-0978-9.Kempf M., Varon E., Lepoutre A., et al. Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001–2011 survey by the French Pneumococcal Netw.ork. Clin Microbiol Infect. 2015;21(1):35–42. https://doi.org/10.1016/j.cmi.2014.08.009Kempf M., Varon E., Lepoutre A., et al. Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001–2011 survey by the French Pneumococcal Network. Clin Microbiol Infect. 2015;21(1):35–42. https://doi.org/10.1016/j.cmi.2014.08.009.Janoir C, Lepoutre A., Gutmann L., et al. Insight into resistance phenotypes of emergent non-PCV13 type pneumococci isolated from invasive disease after PCV13 implementation in France. Open Forum Infect Dis. 2016;3(1): ofw020. DOI: 10.1093/ofid/ofw020Janoir C, Lepoutre A., Gutmann L., et al. Insight into resistance phenotypes of emergent non-PCV13 type pneumococci isolated from invasive disease after PCV13 implementation in France. Open Forum Infect Dis. 2016;3(1):ofw020. DOI: 10.1093/ofid/ofw020.Ouldali N., Levy C., Minodier P., et al. Long-term association of 13-valent pneumococcal conjugate vaccine implementation with rates of community-acquired pneumonia in children. JAMA Pediatr. doi:10.1001/jamapediatrics.2018.5273.Ouldali N., Levy C., Minodier P., et al. Long-term association of 13-valent pneumococcal conjugate vaccine implementation with rates of community-acquired pneumonia in children. JAMA Pediatr. doi:10.1001/jamapediatrics.2018.5273.Azzari C., Serranti D., Nieddu F., et al. Significant impact of pneumococcal conjugate vaccination on pediatric parapneumonic effusion: Italy 2006–2018. Vaccine 37 (2019) 2704–2711 DOI: 10.1016/j.vaccine.2019.04.012.Azzari C., Serranti D., Nieddu F., et al. Significant impact of pneumococcal conjugate vaccination on pediatric parapneumonic effusion: Italy 2006–2018. Vaccine 37 (2019) 2704–2711 DOI: 10.1016/j.vaccine.2019.04.012.Imohl M, Reinert R.R., van der Linden M., et al. Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany. Int J Med Microbiol. 2015;305(7):776–783. https://doi.org/10.1016/j.ijmm.2015.08.031.Imohl M, Reinert R.R., van der Linden M., et al. Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany. Int J Med Microbiol. 2015;305(7):776–783. https://doi.org/10.1016/j.ijmm.2015.08.031.Richter L., Schmid D., Kanitz E.E., et al. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program. PLoS ONE 14(1): e0210081. DOI: 10.1371/journal.pone.0210081.Richter L., Schmid D., Kanitz E.E., et al. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program. PLoS ONE 14(1): e0210081. DOI: 10.1371/journal.pone.0210081.Smith AJ, et al. Presented at: 10th International Symposium on Pneumococci and Pneumococcal Disease (ISPPD); June 28, 2016; Glasgow, Scotland. Poster 285.Smith AJ, et al. Presented at: 10th International Symposium on Pneumococci and Pneumococcal Disease (ISPPD); June 28, 2016; Glasgow, Scotland. Poster 285Waight P.A., Andrews N.J., Ladhani S.N., et al., Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15: 535–43. DOI: 10.1016/S1473-3099(15)70044-7.Waight P.A., Andrews N.J., Ladhani S.N., et al., Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15: 535–43. DOI: 10.1016/S1473-3099(15)70044-7.Palmu A., Rinta-Kokko H., Nohynek H. Long-term impact of ten-valent pneumococcal conjugate vaccine (PCV10) on pneumonia among vaccine-eligible children in Finland. Presented at: 36rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 28 – June, 2015; Malmo; Sweden. May Abstract 0405.Palmu A., Rinta-Kokko H., Nohynek H. Long-term impact of ten-valent pneumococcal conjugate vaccine (PCV10) on pneumonia among vaccine-eligible children in Finland. Presented at: 36rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); May 28 – June, 2015; Malmo; Sweden. May Abstract 0405.Rinta-Kokko H., Auranen K., Toropainen M., et al. Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland. Vaccine 38 (2020) 1559–1564 https://doi.org/10.1016/j.vaccine.2019.11.049.Rinta-Kokko H., Auranen K., Toropainen M., et al. Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland. Vaccine 38 (2020) 1559–1564 https://doi.org/10.1016/j.vaccine.2019.11.049.Dagan R. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation. Expert Review of Vaccines, 18:6, 641–661, DOI: 10.1080/14760584.2019.1627207.Dagan R. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation. Expert Review of Vaccines, 18:6, 641–661, DOI: 10.1080/14760584.2019.1627207.Отчет НИР «Бремя пневмококковой инфекции в Республике Беларусь с позиции здравоохранения и общественного здоровья» № госрегистрации 20181898, 2019 г. С 527, подготовлен ГУ «Республиканский научно-практический центр медицинских технологий, информатизации, управления и экономики здравоохранения» МЗРБ при финансовой поддержке компании Пфайзер.Research report «Burden of pneumococcal infection in the country of Belarus from the standpoint of health and public health» No. of state registration 20181898, prepared by the State Institution «Republican Scientific and Practical Center for Medical Technologies, Informatization, Management and Economics of Healthcare» of the Ministry of Healthcare of the Republic of Belarus with the financial support of Pfizer. (In Russ.).Горбич О. А., Чистенко Г. Н., Дашкевич А. М. и др. Эпидемиологическая характеристика инфекционных агентов, ассоциируемых с внебольничными пневмониями. Мед. Журн. 2017. №4. С. 42–46.Gorbich O.A., Chistenko G.N., Dashkevich A.M., et al. Epidemiologicheskaya harakteristika infekcionnyh agentov, associiruemyh s vnebol’nichnymi pnevmoniyami» // Med. ZHurn.2017;4:42–46 (In Russ.).Л. П. Титов, А. Н. Хархаль, В. А. Горбунов и др. Микрофлора нижних отделов дыхательных путей и резистентность к антибиотикам у детей: результаты мониторинга 2016–2017 гг. Здравоохранение. 2020. №5. С. 5–16.Titov L.P., Kharkhal A.N., Gorbunov V.A., et al. Lower respiratory tract microflora and childish resistance to antibiotics: results of monitoring for 2016-2017. Health-care.2020;5:5-16 (In Russ.).Титов Л. П., Давыдов А. В., Хархаль А. Н. Молекулярно-генетический мониторинг и резистентность к антибиотикам Streptococcus pneumoniae в республике Беларусь. Материалы 3-го Евро-Азиатского саммита специалистов по пневмококковой инфекции 24–25 августа 2019. Доступно на: https://congress-ph.ru/common/htdocs/upload/fm/pnevmokoki/19/prez/11.pdf Ссылка активна на 26 декабря 2020.Titov L.P., Davydov A.V., Harhal’ A.N. Molekulyarno-geneticheskij monitoring i rezistentnost’ k antibiotikam Streptococcus pneumoniae v respublike Belarus’. Materialy 3-go Evro-Aziatskogo sammita specialistov po pnevmokokkovoj infekcii 24–25 avgusta 2019. Available at: https://congress-ph.ru/common/htdocs/upload/fm/pnevmokoki/19/prez/11.pdf. Accessed: 26 Dec. 2020 (In Russ).Давыдов А. В., Титов Л. П., Хархаль А. Н. и др. Чувствительность к антибиотикам штаммов Streptococcus pneumoniae, выделенных от пациентов с менингитом в Беларуси. Здравоохранение. 2018;1:22–32.Davydov A.V., Titov L.P., Harhal’ A.N., et al. CHuvstvitel’nost’ k antibiotikam shtammov Streptococcus pneumoniae, vydelennyh ot pacientov s meningitom v Belarusi. Zdravoohranenie.2018. №1.22–32 (In Russ.).Давыдов А. В., Титов Л. П. Чувствительность к антибиотикам и связь с серотипами штаммов Streptococcus pneumoniae у детей с острым средним отитом и острым синуситом в Беларуси. КМАХ. 2018. Т. 20, №3. С. 206–2015.Davydov A.V., Titov L.P. CHuvstvitel’nost’ k antibiotikam i svyaz’ s serotipami shtammov Streptococcus pneumoniae u detej s ostrym srednim otitom i ostrym sinusitom v Belarusi. KMAH.2018. Tom 20.№3,s. 206–2015 (In Russ.).Давыдов А. В., Титов Л. П., Хархаль А. Н. и др. Связь механизмов генотипической резистентности Streptococcus pneumoniae к антибиотикам с фенотипической резистентностью и серотипами. Известия Национальной академии наук Беларуси. Серия медицинских наук. 2019;16(4):454-467. https://doi.org/10.29235/1814-6023-2019-16-4-454-467Davydov A. V., Titov L. P., Kharkhal A. N., et al. Accociation between molecular mechanisms of antimicrobial resistance, pnenotypes and serotypes in Streptococcus pneumoniae. Vestsi Natsyyanal’nai akademii navuk Belarusi. Seriya meditsinskikh navuk. Proceedings of the National Academy of Sciences of Belarus. Medical series, 2019, vol. 16, no. 4, pp. 454–467 (in Russ.). https://doi.org/10.29235/1814-6023-2019-16-4-454-467ECDC. Surveillance of antimicrobial resistance in Europe 2017. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)ECDC. Surveillance of antimicrobial resistance in Europe 2017. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) Available at: http:// www.belriem.by/images/docs/problemtitov/EARS-NET2017.pdf Accessed: 26 Dec 2020.Титов Л. П., Давыдов А. В., Хархаль А. Н. Молекулярно-генетический мониторинг и резистентность к антибиотикам Streptococcus pneumoniae в республике Беларусь. Материалы 3-го Евро-Азиатского саммита специалистов по пневмококковой инфекции 24-25августа 2019. Доступно на: https://congress-ph.ru/common/htdocs/upload/fm/pnevmokoki/19/prez/11.pdf. Ссылка активна на 26 декабря 2020.Titov L.P., Davydov A.V., Harhal’ A.N. Molekulyarno-geneticheskij monitoring i rezistentnost’ k antibiotikam Streptococcus pneumoniae v respublike Belarus’. Materialy 3-go Evro-Aziatskogo sammita specialistov po pnevmokokkovoj infekcii 24-25 avgusta 2019. Available at: https://congress-ph.ru/common/htdocs/upload/fm/pnevmokoki/19/prez/11.pdf. Accessed: 26 Dec. 2020 (In Russ).Постановление МЗ Республики Беларусь от 18 июля 2012 г. № 106 «Об установлении Национального календаря профилактических прививок, перечня профилактических прививок по эпидемическим показаниям, порядка и сроков их проведения и признании утратившими силу постановлений Министерства здравоохранения Республики Беларусь» от 29 сентября 2006 г. Доступно на: https://pravo.by/upload/docs/op/W21226238_1344546000.pdf. Ссылка активна на 26 декабря 2020.Postanovlenie MZ Respubliki Belarus’ ot 18 iyulya 2012 g. № 106 «Ob ustanovlenii Nacional’nogo kalendarya profilakticheskih privivok, perechnya profilakticheskih privivok po epidemicheskim pokazaniyam, poryadka i srokov ih provedeniya i priznanii utrativshimi silu postanovlenij Ministerstva zdravoohraneniya Respubliki Belarus’» ot 29 sentyabrya 2006 g. Available at: https://pravo.by/upload/docs/op/W21226238_1344546000.pdf Accessed: 26 Dec. 2020 (In Russ).Приказ МЗ Республики Беларусь от 27 февраля 2014 г. №191 «Об утверждении Инструкции по тактике проведения профилактических прививок среди населения в Республике Беларусь». Доступно на: https://normativka.by/lib/document/48859. Ссылка активна на 26 декабря 2020.Prikaz MZ Respubliki Belarus’ ot 27 fevralya 2014 g.№191 «Ob utverzhdenii Instrukcii po taktike provedeniya profilakticheskih privivok sredi naseleniya v Respublike Belarus’» Available at: https://normativka.by/lib/document/48859 Accessed: 26 Dec. 2020 (In Russ).Постановление МЗ Республики Беларусь, 17 мая 2018 г. №42. «О профилактических прививках». Доступно на: http://minzdrav.gov.by/upload/dadvfiles/Нацкалендарь.pdf. Ссылка активна на 26 декабря 2020.Postanovlenie MZ Respubliki Belarus’, 17 maya 2018 g. №42. «O profilakticheskih privivkah». Available at: http://minzdrav.gov.by/upload/dadvfiles/Nackalendar’.pdf. Accessed: 26 Dec. 2020 (In Russ).

The authors declare that there are no conflicts of interest present.